Skip to main content
. 2015 Jul 14;2015(7):CD010294. doi: 10.1002/14651858.CD010294.pub2

AIPRI Study 1996.

Methods
  • Study design: parallel, double‐blind RCT

  • Duration of study: January 1989 to December 1990

  • Follow‐up: 3 years

  • ADPKD assessment: unclear

Participants
  • Countries: Italy, France, Germany

  • Setting: international multicentre study (49 centres)

  • Patients with SCr 1.5 to 4.0 mg/dL (133 to 354 mmol/L); 24‐hour estimated CrCl 30 to 60 mL/min with variations > 30% in at least 3 measurements

  • Number: treatment group (300); control group (283) (64 diagnosed with ADPKD)

  • Mean age ± SD (years): treatment group (51± 13); control group (51 ± 12)

  • Sex (M/F): treatment group (220/80); control group (201/82)

  • Exclusion criteria: therapy‐resistant oedema; treatment with corticosteroids, NSAIDs, or immunosuppressive drugs; UPE > 10 g/24 h; serum albumin < 25 g/L; renovascular hypertension; malignant hypertension or MI or CVA in the 6 months preceding the study; CHF (NYHA class III or IV); insulin‐dependent DM; elevated serum AST concentration; collagen disease; obstructive uropathy; cancer; chronic cough; history of ACEi allergy; drug or alcohol abuse; pregnancy

Interventions Treatment group
  • Benazepril: 10 mg/d


Control group
  • Placebo


Duration of intervention
  • 3 years

Outcomes
  • Doubling SCr concentration

  • SCr

  • UPE

  • DBP

Notes
  • Separate data on ADPKD patients were not provided

  • Funding: not reported

Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Insufficient information to permit judgement
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) 
 All outcomes Low risk Double blind
Blinding of outcome assessment (detection bias) 
 All outcomes Unclear risk Insufficient information to permit judgement
Incomplete outcome data (attrition bias) 
 All outcomes High risk "Sixty‐eight patients in the benazepril group and 61 in the placebo group did not complete the study be cause of death, other adverse events, lack of cooperation, or protocol violations"
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement
Other bias Unclear risk Insufficient information to permit judgement